Table 4.
Multivariate analysis of patients with gastric cancer.
|
Variable |
Univariate survival analysis | Multivariate analysisa | |||||||
|
|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |||||
| Concordance (no/yes) | 0.312 (0.187-0.521) | <.001 | 0.374 (0.220-0.634) | <.001 | |||||
| Age (<70/≥70 years) | 1.265 (0.771-2.075) | .35 | —b | — | |||||
| Gender (male/female) | 1.191 (0.730-1.943) | .48 | — | — | |||||
| ECOGc PSd |
|
|
|
|
|||||
|
|
1 | 0.719 (0.286-1.805) | .48 | — | — | ||||
|
|
2 | 1.092 (0.400-2.983) | .86 | — | — | ||||
|
|
3 (reference) | — | .31 | — | — | ||||
| NRSe 2002 PS (<3/≥3) | 1.231 (0.752-2.018) | .41 | — | — | |||||
| Differentiation type (well, moderate/poor) | 1.769 (0.878-3.563) | .11 | 1.166 (0.571-2.380) | .67 | |||||
| HER2f status (negative/positive) | 1.681 (0.903-3.131) | .10 | 0.986 (0.517-1.881) | .97 | |||||
| cStageg |
|
|
|
|
|||||
|
|
I | 0.000 (0.000-5.030) | .97 | 0.000 (0.001-9.960) | .97 | ||||
|
|
II | 0.066 (0.009-0.481) | .01 | 0.087 (0.012-0.638) | .02 | ||||
|
|
III | 0.400 (0.248-0.646) | <.001 | 0.417 (0.256-0.678) | <.001 |
||||
|
|
Ⅳ (reference) | — | <.001 | — | .001 | ||||
aMultivariate model included concordance, differentiation type, HER2 status, and clinical stage. Enter model selection was performed.
bNot applicable.
cECOG: Eastern Cooperative Oncology Group.
dPS: performance status.
eNRS: nutrition risk screening.
fHER2: human epidermal growth factor receptor 2.
gcStage: clinical stage; TNM-8, the Union for International Cancer Control 8th edition and American Joint Committee on Cancer 8th edition.